MARKET

ZURA

ZURA

Zura Bio Limited
NASDAQ
4.930
-0.280
-5.37%
After Hours: 4.790 -0.14 -2.83% 16:36 09/15 EDT
OPEN
5.20
PREV CLOSE
5.21
HIGH
5.24
LOW
4.740
VOLUME
2.63M
TURNOVER
--
52 WEEK HIGH
7.44
52 WEEK LOW
1.880
MARKET CAP
472.44M
P/E (TTM)
-4.4057
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ZURA last week (0907-0911)?
Weekly Report · 1d ago
Weekly Report: what happened at ZURA last week (0831-0904)?
Weekly Report · 09/07 09:48
Zura Bio management to meet with Piper Sandler
TipRanks · 09/04 19:10
Zura Bio to Participate in the Cantor Global Healthcare Conference
Barchart · 08/31 15:30
Weekly Report: what happened at ZURA last week (0824-0828)?
Weekly Report · 08/31 09:52
JATT III Acquisition Corp Announces Pricing of $60,000,000 Initial Public Offering
Barchart · 08/25 18:00
Weekly Report: what happened at ZURA last week (0817-0821)?
Weekly Report · 08/24 09:53
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 08/21 18:57
More
About ZURA
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.

Webull offers Zura Bio Ltd stock information, including NASDAQ: ZURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZURA stock methods without spending real money on the virtual paper trading platform.